CSX Shares Rise on Q3 Earnings Beat

CSX shares rose 4.2% in pre-market trading after the company posted better-than-expected Q3 results, with revenue of $3.59 bln and adjusted earnings of 44 cents per share. Other stocks moving in pre-market trading include Artiva Biotherapeutics, Safe & Green Holdings, and Kezar Life Sciences, which surged 98.6%, 38.8%, and 36%, respectively. Losers include INVO Fertility, Earlyworks Co, and American Battery Technology, which declined 34.6%, 33.9%, and 19.8%, respectively.

CSX Corp. (NYSE: CSX) shares rose 4.2% in pre-market trading on September 12, 2025, following the release of its third-quarter earnings report. The railroad operator reported adjusted earnings of 44 cents per share, exceeding analyst expectations by one cent. Revenue stood at $3.59 billion, in line with forecasts but down 1% year-on-year, according to an InvestorsHub report an InvestorsHub report.

The company's results were driven by a 1% increase in total shipment volumes to 1.61 million units, largely due to intermodal gains. However, export coal and merchandise volumes fell, reflecting broader economic trends, the report said.

New CEO Steve Angel highlighted the strength of CSX's rail network and its potential for long-term expansion. Angel also signaled openness to strategic options, fueling speculation about a potential merger with BNSF Railway, owned by Berkshire Hathaway. This comes amid recent consolidation efforts in the rail sector, such as the $85 billion deal between Union Pacific and Norfolk Southern, the article noted.

Ancora Holdings, an activist investor, has been pushing for strategic moves, including a merger. Angel's appointment as CEO followed Ancora's calls for leadership changes, the coverage added.

Analysts at BMO Capital Markets noted that CSX has a "self-help opportunity" and could deliver EPS/cash flow and valuation upside with strong execution. They believe this positioning will strengthen the company's negotiation power in any future consolidation, the piece reported.

Other notable pre-market movers include Artiva Biotherapeutics, Safe & Green Holdings, and Kezar Life Sciences, which surged 98.6%, 38.8%, and 36%, respectively. Meanwhile, INVO Fertility, Earlyworks Co, and American Battery Technology declined 34.6%, 33.9%, and 19.8%, respectively, according to an Investing.com report an Investing.com report.